CN1678625A - 人源化抗淋巴毒素β受体的抗体 - Google Patents

人源化抗淋巴毒素β受体的抗体 Download PDF

Info

Publication number
CN1678625A
CN1678625A CNA038207214A CN03820721A CN1678625A CN 1678625 A CN1678625 A CN 1678625A CN A038207214 A CNA038207214 A CN A038207214A CN 03820721 A CN03820721 A CN 03820721A CN 1678625 A CN1678625 A CN 1678625A
Authority
CN
China
Prior art keywords
antibody
ser
val
thr
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038207214A
Other languages
English (en)
Chinese (zh)
Inventor
埃伦·加伯
肯尼思·西蒙
乔斯·萨尔达纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN1678625A publication Critical patent/CN1678625A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA038207214A 2002-07-01 2003-07-01 人源化抗淋巴毒素β受体的抗体 Pending CN1678625A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39299302P 2002-07-01 2002-07-01
US60/392,993 2002-07-01
US41737202P 2002-10-09 2002-10-09
US60/417,372 2002-10-09

Publications (1)

Publication Number Publication Date
CN1678625A true CN1678625A (zh) 2005-10-05

Family

ID=30003289

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038207214A Pending CN1678625A (zh) 2002-07-01 2003-07-01 人源化抗淋巴毒素β受体的抗体

Country Status (10)

Country Link
US (1) US7429645B2 (enExample)
EP (1) EP1539793A4 (enExample)
JP (1) JP2005532051A (enExample)
CN (1) CN1678625A (enExample)
AR (1) AR040367A1 (enExample)
AU (1) AU2003248782A1 (enExample)
CA (1) CA2491480A1 (enExample)
NZ (1) NZ537965A (enExample)
TW (1) TW200416044A (enExample)
WO (1) WO2004002431A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113194985A (zh) * 2018-10-26 2021-07-30 伊缪诺金公司 EpCAM抗体、可活化抗体和免疫缀合物及其用途
CN115087670A (zh) * 2019-12-11 2022-09-20 西拉格国际有限责任公司 包含ltbr和edb结合结构域的多特异性结合分子及其用途

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
SG121778A1 (en) * 1998-10-09 2006-05-26 Univ Emory Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
SK5672003A3 (en) * 2000-10-13 2003-10-07 Biogen Inc Humanized anti-LT-beta-R antibodies
PL377611A1 (pl) * 2002-12-20 2006-02-06 Biogen Idec Ma Inc. Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi
CN100473664C (zh) * 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
CA2529945A1 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
JP2005241389A (ja) * 2004-02-25 2005-09-08 Ochiyanomizu Jiyoshi Univ 蛍光標識糖鎖の特異的固定化試薬および固定化方法
WO2005092927A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP2067041A2 (en) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarkers and assays for the treatment of cancer
PE20080980A1 (es) 2006-10-12 2008-09-02 Genentech Inc Anticuerpos anti-linfotoxina alfa
CA2666934A1 (en) * 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
PL2158315T3 (pl) 2007-06-25 2016-10-31 Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
AU2009334498A1 (en) * 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2025012620A1 (en) 2023-07-07 2025-01-16 Mestag Therapeutics Ltd Binding constructs
EP4527851A1 (en) 2023-09-22 2025-03-26 Bayer Aktiengesellschaft Bispecific antibodies binding ltbr and lrrc15
WO2025172588A1 (en) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Bispecific constructs directed against fap and ltbr
WO2025172587A1 (en) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Binding constructs
WO2025221728A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69132629T2 (de) 1990-06-27 2002-04-18 Biogen, Inc. Oberflächenkomplexbildung von lymphotoxin
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69334224D1 (de) 1992-12-04 2008-07-17 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
DE69632681T2 (de) * 1995-01-26 2005-06-09 Biogen, Inc., Cambridge Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
AU752710B2 (en) 1998-01-30 2002-09-26 Biogen Idec Ma Inc. Treatment of follicular lymphomas using inhibitors of the lymphotoxin (LT) pathway
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
SK5672003A3 (en) 2000-10-13 2003-10-07 Biogen Inc Humanized anti-LT-beta-R antibodies
PL377611A1 (pl) 2002-12-20 2006-02-06 Biogen Idec Ma Inc. Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi
CN100473664C (zh) 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
WO2005092927A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113194985A (zh) * 2018-10-26 2021-07-30 伊缪诺金公司 EpCAM抗体、可活化抗体和免疫缀合物及其用途
CN115087670A (zh) * 2019-12-11 2022-09-20 西拉格国际有限责任公司 包含ltbr和edb结合结构域的多特异性结合分子及其用途

Also Published As

Publication number Publication date
JP2005532051A (ja) 2005-10-27
WO2004002431A2 (en) 2004-01-08
US7429645B2 (en) 2008-09-30
CA2491480A1 (en) 2004-01-08
WO2004002431A3 (en) 2004-08-26
EP1539793A2 (en) 2005-06-15
AU2003248782A1 (en) 2004-01-19
AR040367A1 (es) 2005-03-30
US20060222644A1 (en) 2006-10-05
EP1539793A4 (en) 2006-02-01
NZ537965A (en) 2008-04-30
TW200416044A (en) 2004-09-01

Similar Documents

Publication Publication Date Title
CN1678625A (zh) 人源化抗淋巴毒素β受体的抗体
CN1547590A (zh) 人源化抗-LT-β-R抗体
CN1271205C (zh) 重新构建的人抗hm1.24抗体
CN1211123C (zh) 抗白细胞粘附分子vla－4的人源化抗体
CN1662558A (zh) 人cd22特异性抗体及其治疗和诊断应用
CN1823163A (zh) 针对胰岛素样生长因子ⅰ受体的抗体及其应用
CN1898264A (zh) 用新的抗il13单克隆抗体治疗癌症
CN1541224A (zh) 拮抗性抗-hTNFSF13b人抗体
CN1889978A (zh) 干扰素α抗体及其用途
CN1922210A (zh) 可用作治疗剂的单价抗体片段
CN1902231A (zh) 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体
CN101035809A (zh) 抗tag－72的人源化单克隆抗体
CN1277632A (zh) 天然人源化抗体
CN1729203A (zh) 抗cd20的人单克隆抗体
CN1646161A (zh) 自身免疫疾病的药剂和治疗方法
CN1602317A (zh) 血管生成素－2的特异结合剂
CN1795009A (zh) 抗－cd33抗体和使用其治疗急性髓性白血病的方法
CN1889979A (zh) Ip－10抗体及其用途
CN1575303A (zh) 人cdr－移植抗体及其抗体片段
CN1469925A (zh) 低分子化的tpo激动剂抗体
CN1189190A (zh) 抗人白介素－5受体α链的抗体
CN1440424A (zh) 对于肿瘤坏死因子相关细胞凋亡诱导配体受体选择性的抗体及其应用
CN1798765A (zh) 多价淋巴毒素β受体激动剂及其治疗用途
CN1283662C (zh) 拮抗性抗hFAS配基人类抗体及其片段
CN1950107A (zh) Irta－5抗体及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication